MedTech is an industry where the regulatory hurdles are so high that many companies make the mistake of treating CE marking as success. But CE marking isn't even the starting point for commercial success.
What I've seen over 15 years in the industry: most post-launch problems are commercial problems, not product problems. The wrong target audience. Value that isn't communicated to the right decision-makers. No sales channel that matches the complexity of the product. Pricing that doesn't align with how customers budget and buy.
The five most common mistakes after a MedTech launch
1
The wrong first point of contact
The team approaches the physician or technician. But the decision may ultimately sit with the purchasing committee, hospital leadership, or CFO. If you don't speak their language, your message goes nowhere.
2
Technical value instead of clinical value
"Our sensor has a 200 Hz sampling rate" doesn't matter to someone buying outcomes. What matters is earlier detection, fewer complications, and lower process costs.
3
No sales channel built for B2B complexity
MedTech purchasing decisions take 6 to 18 months and require trust built over time. An online store or inbound-only approach doesn't work as the primary channel for this kind of buying process.
4
Pricing that doesn't fit the customer's budget structure
Hospitals and clinics operate within fixed budget cycles and procurement processes. A price that doesn't fit their capital or operating expense structure is unlikely to get approved.
5
No reference strategy
MedTech buyers rely heavily on references. Without pilot partners and documented case studies, the product remains stuck in "interesting, but unproven."
What helps instead: five commercial priorities after launch
1
Build a KOL strategy before going broad
Bring key opinion leaders in the target indication on board as early partners. They give the product credibility across the broader market, often more valuable than any marketing budget.
2
Map the hospital decision structure
Who decides, who recommends, who blocks? Build an account map for every target customer, with multiple stakeholders on your radar, not just one.
3
Build a health economics case
Calculate and document ROI in terms of cost avoidance, increased capacity, and fewer complications, not technical metrics. That's the language budget decision-makers speak.
4
Run a pilot program with clear success criteria
Structure the pilot around defined KPIs, a clear timeline, and decision criteria for moving into regular use. Not an open-ended "let's just try it."
5
Clarify the reimbursement path
Is the product reimbursable? Under which codes? In which markets? Reimbursement isn't a sales bonus. It's often a prerequisite for the purchase decision.
The MedTech commercial funnel is not a sales funnel
The MedTech buying process has six phases that often run in parallel and iteratively rather than sequentially:
- Awareness: publications, conferences, KOL network
- Interest: clinical data, peer recommendations, webinars
- Evaluation: pilot requests, demos, benchmarking against the existing solution
- Committee review: a multi-stakeholder decision involving clinical teams, IT, procurement, and compliance
- Procurement: tender, negotiation, budget approval
- Implementation: training, support, change management
In MedTech, nobody buys a product. They buy a decision they can defend to their committee, their leadership, and their patients.
Checklist: are you ready to launch?
□ Stakeholder map: Do you know who decides, who recommends, and who blocks?
□ Health economics case: Is the ROI expressed in terms that matter to the hospital?
□ Pilot program design: Have you defined clear criteria for pilot partners and pilot success?
□ Reimbursement status: Have you clarified the reimbursement situation in your target markets?
□ KOL identification: Have you identified your first reference partners in the target indication?
□ Value communication: Are you communicating outcomes and costs rather than features?
An excellent product deserves an excellent commercial strategy. In MedTech, that isn't a given — and it isn't a luxury. It's what allows a good solution to actually reach the patients it was developed for.